Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SBAT(.60)...shell's owner planning large China investments.....
1M shares outstanding
$600K market cap
63.5% of the shell owned by Viking Investments Group
The SBAT shell continues to be an extremely attractive speculative investment because of its structure and still relatively low valuation. I think it has become even more attractive, IMO, now that it looks like something significant is going on behind the scenes with the shell's owner (Viking Investments).
While many China-related investment firms have been somewhat retrenching during all the turmoil surrounding China-based investments/stocks, it is interesting to note that Viking Investments Group has actually been accelerating its job advertising for its China office. The number/scope of its job postings has very noticeably increased in the last few months.
About 2 weeks ago I noticed that Tom Simeo (CEO of Viking and SBAT) started posting on a LinkedIn China networking forum. It appears that Viking would like to invest $100M in Chinese companies by the end of 2011.......
US $ 100 MILLION TO BE INVESTED IN CHINESE COMPANIES BEFORE THE END OF THE YEAR!
HELP US TO FIND THE GOOD TRANSACTIONS.
WE PAY EXCELLENT REFERRAL FEES. WE COMMIT TO INVEST WITHIN TWO WEEKS.
MOST INDUSTRIES ARE OK, EXCEPT FOR NO REAL ESTATE AND NO STATE OWNED COMPANIES. MUST BE PROFITABLE WITH AT LEAST TWO YEARS OF HISTORY AND 20% GROWTH. MUST BE WILLING TO LIST IN THE UNITED STATES. WE ARE NOT PE OR VC.
WE INVEST WHEN YOU LIST IN THE US. WE ARE LOCATED IN SHANGHAI, CHINA AND NEW YORK, UNITED STATES. SEND US AN EMAIL IN ENGLISH OR CHINESE.
China-based equity fund investment, financing at $5.....
There has been an interesting development, which started appearing on my scans last week. Based on what I am seeing, it probably wouldn't surprise me if some type of filings/announcements start showing up "relatively soon".
Recently, the China Soong Ching Ling Foundation International Investment Company (parent company is the China Soong Ching Ling Foundation) formed a new equity investment fund. It appears that the first two investments are CBDH and a nanotechnology/energy company. From what I understand, the fund intends to provide assistance in the areas of private placements, mergers & acquistions, general growth, road shows, etc.
A 6/29/2011 news item on the fund's website mentions that CBDH stock subscription units are being sold at $5 until July 10, after that date the price increases to $6......
China Sheng Yongsheng things Pharmaceutical Holdings Limited ("China Yong Sheng", stock code: CDBH) stock price was June 28, 2011 Rose to $ 8.76 dollars / share, taking into consideration the majority of the work to carry out investment partners and interests, China Yong Sheng current stock price of $ 5 dollars subscription / units to maintain July 10, 2011 No adjustment July 10 After the subscription price by $ 6 dollars /shares. That the same amount of investment, reduce the number of shares. Hope the majority of investors, informed each other, seize the time to subscribe.
UPRD(.05)...shell.....
8.1M shares outstanding
50+% of the shell owned by Albert Zlotnick (87 years old)
I accumulated a position in the UPRD shell last week at 4 cents. This is an extremely high risk type of shell because the last SEC filing was in 2002, and no 15-12G filing has been made. So obviously there is a considerable risk of the registration getting revoked.
Aside from the possibility of a RM in the works (see UPRD message board), the shell is fairly attractive from a structural standpoint. As far as I can tell from the last filing, UPRD should be relatively clean and not saddled with the kind of baggage you might find with shells in a similiar situation.
TGFN(.011)...expecting merger in 2011......
Somewhat notable change in the "plan of operation" verbiage between the last two filings. The latest filing (2010 10-K) has more of an emphasis on a merger/acquisition of another company during calendar 2011......
The company plans to merge with or acquire an existing company during the year ending December 31, 2011. Should the acquired or merged operating entity not have sufficient resources of its own to fund the combined entity’s operations, the Company will issue stock to raise sufficient operating capital.
nsomniyak...AHAG......
Do you expect anything imminently from AHAG, or is it more one to buy and stick under the mattress for a couple years?
stanley01...AHAG position.....
How many shares do you hold of AHAG? I own 350,000 and am holding them long term. Crazy to think I owe 4.9% of the stock.
RNPR(.10)...shell.....
1) 3.8M shares outstanding
2) 3 Chinese investors own 3.45M shares (90+% of the shell)
3) One of the investors (Rui Mai, involved in venture capital and land development) purchased a fully-diluted 25+% position in another stock I own (DION) during calendar 2010 (filings are expected to be made soon).
I picked up a few shares of the RNPR shell during 2010 when the price dropped down into the 6-cent area. The net valuation of the shell at that price was well under $300k.
Song Yakun purchased control of the shell in December 2009 (2M shares at .066). I don't know whether she is planning on reverse merging any company she currently is involved with or whether she will pursue a completely third party type of RM.
She has been primarily involved with processed food companies in China over the last 15 years. The company she currently is Chairman of was apparently struggling prior to her arrival in the 1990s, and the job she has done there has garnered attention in the form of nominations for entrepreneur and brand recognition awards. The last link below is a dated piece (probably from 2006) in which you can find some history of that company and future growth plans (which included development of a fast-food franchise).
Last year I recall running across her Netlog page in China, and most of the colleagues listed on that site were connected to food companies. One in particular that caught my eye was the CEO of Nestle (China).
Couple items of interest.....
http://www18.hkbu.edu.hk/~uao/foundation/eng/news.php?offset=33&n=2010034
http://translate.google.com/translate?hl=en&sl=zh-CN&u=http://www.jlcity.gov.cn/headinfo/infocontent.jsp%3Finfoid%3D17525&ei=rd0YTaysMeHhnQeyp7CGDg&sa=X&oi=translate&ct=result&resnum=7&ved=0CGwQ7gEwBjge&prev=/search%3Fq%3D%2522%25E5%25AE%258B%25E4%25BA%259A%25E5%259D%25A4%2522%26start%3D30%26hl%3Den%26lr%3Dlang_zh-CN%26sa%3DN%26tbas%3D0%26tbs%3Dlr:lang_1zh-CN%26prmd%3Divns
Business development job posting.....
The company is looking for 2 business development people and 4 financial advisory assistants. And for the first time that I can recall, Viking is now advertising for Chief Financial Officers for its client companies (currently seeking 2 CFOs).......
stanley01...AHAG(.015)......
AHAG is a clean shell--- only 7 million shares outstanding, tiny float, and the former CEO Lawrence Butler is owner of TalkTrash FCM, a creative advertising company. I think one day he will reverse merge the two companies and AHAG stock will explode. AHAG's physical address shares the same physical address as TalkTrash FCM.
Larry Butler, chief executive of advertising firm TrashTalk FCM in Brentwood, has been using the site for a couple of months now and has built an investment portfolio of more than a half-million dollars in private company stock.
He said he appreciates the opportunity to invest in hot companies that have already gained the backing of top venture capital firms.
“It is creating an opportunity to make shares in private companies more accessible to the public,” he said. “I would have never had an opportunity to buy shares in Facebook, for instance, if it wasn’t for SharesPost.”
Viking Investments...job ads in March/April.....
Interesting to note that Viking Investments (majority control owner of SBAT) has placed a number of job advertisements here in March/April 2011.
The company is looking for 2 business development people and 4 financial advisory assistants. And for the first time that I can recall, Viking is now advertising for Chief Financial Officers for its client companies (currently seeking 2 CFOs).......
http://tinyurl.com/3hr35xb
MSCGro info...fertility drug tech.....
Although it has not yet been placed on the Vitro Biopharma website, you can find some additional information about VODG's cell culture media (now branded "MSCGro") on HemoGenix's new website which came online recently......
http://www.hemogenix.com/prod_MCA.php
Regarding the private message I received recently, asking if I know anything about the identity of the offshore third party interested in VODG's fertility drug technology. Although this is purely a guess on my part, the term "renewed interest" (see below) leads me to believe that maybe BioCare Europe has been expressing interest in the technology again.
BioCare Europe (an Italian biotech company founded and run by Dr. Luca Trama) was publicly acknowledged by VODG some 5+ years ago as being interested in VODG's fertility drug platform. I think BioCare Europe uses FSH (follicle-stimulating hormone) in some of its products, and I recall seeing the company participated in the funding of some fertility-related clinical trials along with Merck Serono (which controls a large segment of the FSH market).
But, again, that is just my best guess at the moment.
Also, there is renewed interest by an offshore third party in commercialization of the Company’s fertility drug product and technology portfolio.......
.....During 2010, we began negotiations for out-licensing of our patented technology related to FSH manufacture. We anticipate establishment of a license agreement in the near future. We may also provide the licensee with assistance in sourcing necessary raw materials, distribution of finished product and options to advanced stem-cell based methods for FSH production.
temp...Nemer Hassey.....
It seems we have a VP of Planning and development.
Mr. Nemer E. Hassey
sg.finance.yahoo.com/q/pr?s=CDBH.PK
Nemer E. Hassey, Vice President
Mr. Hassey provides Cienega Creek with expertise in fitness facility planning and development. Concurrently he holds the positions of assistant principal and head football coach at Cienega High School (CHS) in Vail, Arizona. Prior to CHS Mr. Hassey served four years as head football coach at Sahuaro High
School (SHS) in Tucson, Arizona. Mr. Hassey holds a bachelors degree in Education from the University of Arizona and a master's degree from Northern Arizona University.
queens9000...Jiao Xuding.....
I guess the two board members, CEO and CFO are increasing their common share holdings slowly after they took 97% of preferred voting power.
For common shares, now they are 5 major investors for SUIP.
The 3 investors and 2 board members. I don't know Jiao Xuding is still the share holder. He purchased 19M shares at 0.04. I don't see any filing after his purchase, so I assume he's still a share holder.
On October 30, 2008, the Board of Directors of Sunrise authorized the termination and rescission of its previous sales of its common stock and stock purchase warrants in the aggregate amount of $3,000,000 that were sold by the Corporation to three non-us investors during January 2008. The Corporation have returned investors in the aggregate amount of $2,933,128, which includes (1): $750,000 cash to Weiquan Tian; (2) $750,000 cash to Xuding Jiao; (3) $900,000 cash and a convertible secured promissory note in the principal amount of $500,000 (U.S.) and its accrued interests of $33,128 (U.S.) from SJ Electronics, Inc. to Xuguang Sun and cancelled all the outstanding shares of common stock and stock purchase warrants previously issued to them.
Livingstone821/deet49...risk/reward, SUIP.....
Livingstone821: I don't have private message response capability, so I can only respond via public message. Personally, I will be disappointed if I walk away from my SUIP investment with anything less than a 10-bagger (which means I am looking for at least 30 cents).
When I am looking to make an entry into a shell (or significantly increase my position), I usually pay fairly close attention to net valuation (market cap + debt - cash) and share structure. Granted, there are a lot of variables involved in shell investing. Sometimes the shells that look least attractive on paper do extremely well, and sometimes it is the low market cap and low share structure shells that perform well. But I see nothing inherently wrong with focusing on a strategy of concentrating a person's shell investments on those shells that provide a theoretical optimal risk/reward: low net valuations with attractive share structures.
At my cost basis on SUIP, I purchased a fully-reporting bulletin board shell with a market cap around $200K. At that kind of valuation I consider the long-term downside risk to be relatively minimal, and the upside potential to be quite significant. As I have mentioned before, when you look around IHUB at the kinds of valuations that some shells are selling at it just gives you an additional appreciation of how fundamentally attractive a lot of these "value" shells like SUIP really are. Generally speaking, a $200K shell with 7M shares outstanding should offer a more attractive investment profile than a $10M shell with 100M shares outstanding.
deet49: Only time will tell if that share issuance is a harbinger of any upcoming significant/positive change in corporate activity. But it definitely caused my eyebrow to raise a little because it seems historically "unusual" for the Suns to focus on a single quarter.
If I recall correctly, back several years ago Tim Sun issued himself around 1+M shares in advance of a full year of services on the other company he is involved with (SGBL). But as far as I remember this SUIP issuance is the first time the Suns have issued any shares for services to be performed in just a specific quarter. SGBL will probably be filing its quarterly report in the next week or two, so it will be interesting to see if there is any similiar share issuance activity on that stock. If there is not a similiar issuance on SGBL, it will cause my eyebrow to raise a little more.
MWM...TSAS.....
For what it is worth, there are a number of things regarding TSAS that would make me a little uncomfortable. The PRE 14C filed on 2/09/2011 provides quite a bit more information regarding the share structure, potential assets to be acquired, and the financial situation.
1) The current shares outstanding are 204M, giving the TSAS new venture a current market cap of $100+M.
2) Nowhere in the filing (unless I completely missed it) is there any mention of that $100M financing that was secured in 2010. Nor is there are any mention of any other completed financing. Instead the only mention of financing is the proposed private placement of its preferred stock at the equivalent of $1.25 per share, and the proposed $100M convertible note financing at $2 per share.
3) Now, whether TSAS can actually complete those financings at the target prices remains to be seen. But I don't think it is particularly encouraging that TSAS has entered into a financing and investor relations agreement with Wakabayashi Fund (which has had some problems with the SEC in the past), so I think that could make some potential investors uncomfortable.
http://knobias.10kwizard.com/filing.php?param=&ipage=7394548&DSEQ=1&SEQ=&SQDESC=SECTION_BODY&exp=
600K share issuance....interesting.....
According to the 10-Q filed on Friday, there was a total 600K share issuance to the CEO and the CFO on January 5, 2011, which brings management's direct holdings up to about 1.13M shares and the total outstanding up to about 6.9M shares.
What I find rather interesting is that the shares were issued at the beginning of SUIP's 2Q (January-March 2011) and it specifically states that the shares are for services to be rendered during this quarter.......
On January 5, 2011, Sunrise issued 600,000 shares of its restricted common stock to its Chief Executive Officer and Chief Financial Officer for their services during the three month period ended March 31, 2011. These shares were valued at $0.0258 per share based on the market close price for the Company's Common Stock on January 4, 2011 which will be recorded as a contribution of capital for the value of the shares and an equivalent amount to stock based compensation.
chinamuscabio.com website......
The China Domestica Bio-technology Holdings website was registered on September 14 (a little less than 2 weeks ago). The site started coming online within the last 1-2 days......
www.chinadomestica.com/
VODG(.12)...license agreement expected......
There could be a number of potentially interesting developments and press releases coming from VODG in calendar 2011. If the competitive advantages of its VitroGrow culture media are as distinct as indicated, it is probably only a matter of time before the product begins to gain much more significant traction in the market. And the indications coming from the last 10-Q and 10-K suggest the fertility drug technology is now back in play with an expectation of a license agreement being signed in 2011.
VitroGrow: An item from the 10-K filed on Friday, pertaining to the VitroGrow product line.....
The Company believes it has significant prospective sales opportunities that management is pursuing to the full extent possible. These efforts have been bolstered by a recently completed Company study showing performance advantages of its VitroGrow™ Brand of stem cell media over major leaders of this market segment. We plan to leverage the competitive advantages of our VitroGrow™ product line into significant penetration of this market through alliances with major distributors of life science products. The Company is engaged in discussions with prospective partners and intends to pursue development of these business relations to the full extent possible. These potential partners possess manufacturing capabilities and well-established, global distribution channels, but lack product offerings that are equivalent to the VitroGrow™ stem cell media product line
Management is engaged with numerous current and prospective customers regarding product sales and there are several opportunities for collaboration with other firms and university researchers working in the stem cell sector that may lead to strategic alliances further expanding sales of the Company’s products and development of new products targeting stem cell research and drug development. Also, there is renewed interest by an offshore third party in commercialization of the Company’s fertility drug product and technology portfolio.
The Company's previous manufacture and sale of purified antigens for diagnostic purposes resulted in the discovery of several products and technologies with potential application for therapeutic purposes. An initial target was the pituitary hormone FSH and related products, since FSH has been used as a drug to treat infertility for the past 35 years. The worldwide market for FSH and related products is approximately $1.3 billion per year. However, in the recent past, the Company has utilized its limited resources for its stem cell research in an effort to establish financial support and revenue from product sales in the near term. During 2010, we began negotiations for out-licensing of our patented technology related to FSH manufacture. We anticipate establishment of a license agreement in the near future. We may also provide the licensee with assistance in sourcing necessary raw materials, distribution of finished product and options to advanced stem-cell based methods for FSH production. The Company's stem cell technology has potential application to generation of new cell lines for FSH production but this development would require additional R&D to demonstrate feasibility.
Management anticipates substantially larger increases in revenue during fiscal year 2011 due to a shifted focus to the establishment of distribution agreements for sales of VitroGrow™ Media as described in greater detail in Section 1 and out-licensing of its patented and patent-pending technology related to treatment of infertility.
VODG(.12)...license agreement expected......
There could be a number of potentially interesting developments and press releases coming from VODG in calendar 2011. If the competitive advantages of its VitroGrow culture media are as distinct as indicated, it is probably only a matter of time before the product begins to gain much more significant traction in the market.
An item from the 10-K filed on Friday, pertaining to the VitroGrow product line.....
The Company believes it has significant prospective sales opportunities that management is pursuing to the full extent possible. These efforts have been bolstered by a recently completed Company study showing performance advantages of its VitroGrow™ Brand of stem cell media over major leaders of this market segment. We plan to leverage the competitive advantages of our VitroGrow™ product line into significant penetration of this market through alliances with major distributors of life science products. The Company is engaged in discussions with prospective partners and intends to pursue development of these business relations to the full extent possible. These potential partners possess manufacturing capabilities and well-established, global distribution channels, but lack product offerings that are equivalent to the VitroGrow™ stem cell media product line
Management is engaged with numerous current and prospective customers regarding product sales and there are several opportunities for collaboration with other firms and university researchers working in the stem cell sector that may lead to strategic alliances further expanding sales of the Company’s products and development of new products targeting stem cell research and drug development. Also, there is renewed interest by an offshore third party in commercialization of the Company’s fertility drug product and technology portfolio.
The Company's previous manufacture and sale of purified antigens for diagnostic purposes resulted in the discovery of several products and technologies with potential application for therapeutic purposes. An initial target was the pituitary hormone FSH and related products, since FSH has been used as a drug to treat infertility for the past 35 years. The worldwide market for FSH and related products is approximately $1.3 billion per year. However, in the recent past, the Company has utilized its limited resources for its stem cell research in an effort to establish financial support and revenue from product sales in the near term. During 2010, we began negotiations for out-licensing of our patented technology related to FSH manufacture. We anticipate establishment of a license agreement in the near future. We may also provide the licensee with assistance in sourcing necessary raw materials, distribution of finished product and options to advanced stem-cell based methods for FSH production. The Company's stem cell technology has potential application to generation of new cell lines for FSH production but this development would require additional R&D to demonstrate feasibility.
Management anticipates substantially larger increases in revenue during fiscal year 2011 due to a shifted focus to the establishment of distribution agreements for sales of VitroGrow™ Media as described in greater detail in Section 1 and out-licensing of its patented and patent-pending technology related to treatment of infertility.
RichieBoy...debt, SUIP management, connections.....
"I note from the filing SUIP is (albeit slowly) paying down debt and there is this interesting tidbit...
Supplement disclosure of non cash investing and financing activities:
Reduction of note in connection with share recission
$500,000
My hunch is either he is looking to do exploration OR! he is prettying up the shell to flog it. Hard to tell yet."
SUIP management has been pretty shareholder friendly from the perspective of a shell investor, IMO. Debt and expenses have been kept relatively low up to this point. The only significant amount of debt the shell had in its history was a $200K loan (convertible at 10 cents per share) from the CEO when the shell was spun off. The CEO decided not to make the conversion, which helped maintain the low share structure.
That "$500,000" you referenced was the $500K convertible investment/note that SUIP purchased a couple of years ago.
For historical/background purposes: Back in 2008, the CEO invested $1.5M and 2 other people each invested $750K (total of $3M) in SUIP. Part of the new business plan was for SUIP to make investments in other companies. The first investment was the purchase of a $500K convertible note in an electronics-related company. Unfortunately the timing of the investment turned out to be particularly bad -- about 3 months or so before the global credit markets collapsed.
This is a snippet of comments I had about this from post #36.....
I was actually somewhat impressed by an action SUIP took last year to restore shareholder value to the shell after SUIP management basically got blindsided by the events that transpired surrounding SJEL (the company that it purchased a $500K convertible note from). That $500K came from the $3 million that the CEO and his associates invested in SUIP in early 2008.
I don't have the time/energy to go back through SJEL's filings but from what I recall just a few months after SUIP purchased that note a large international financial institution unexpectedly pulled some loan or line of credit from SJEL. This created an extremely serious financial situation for SJEL almost overnight, and it potentially could have resulted in SUIP shareholders losing that $500K.
SUIP's management did something you rarely see. The CEO basically took personal responsibility for that situation. The CEO took ownership of that note, and then completely restored SUIP to its original shell condition prior to their $3 million investment. Unless SJEL has recovered financially from that incident, it is entirely possible that SUIP's CEO may have taken a personal $500K hit. And thanks to his efforts to insulate other shareholders, SUIP shareholders managed to emerge from this unscathed.
temp...website, other items.....
"Not a lot of progress since then, but maybe some?
www.chinadomestica.com/index.asp
Does this look new?"
As far as I recall, the information that is currently on the website appeared there in the first few days/weeks that the site went online.
The filing of the 10-K and the 8-K (change in auditor) suggests that the company does intend to regain compliance with its filings. The annual report was also interesting, IMO, because it revealed for the first time that the former CEO Michael Klinicki retained more than 4% of the shell, had contact with the company in September, and agreed to waive 9K in debt. The "tradeable" float on CDBH is probably well below 20K shares.
The latest job advertisement has the company looking for two people for accounting (January 11)......
http://tinyurl.com/2vd85of
The Fuzhou Daily had a November news item about the overall growth that is occurring at the industrial park where the company's new production base expansion project is located. The project is the first company mentioned in the second paragraph.....
http://tinyurl.com/4cvxhs4
For reference purposes, the link below is for the Fuzhou Daily news item back in January 2010 when the ground-breaking ceremony for the company's expansion project was announced. If I recall correctly subsequent news items I saw stated that the project was expected to be completed around the end of 2010, so if all of that information is accurate it is possible the production base could already be complete (or near complete) and operational in 2011.....
http://tinyurl.com/46gw88m
Walker...YCKM.....
The odds probably favor that the mobile communications products firm will most likely be the RM candidate, but I think the primary question here is exactly what will the final structure of the RM look like and the current/future valuation.
Part of what makes it difficult to determine/guess what the final structure might look like is the fact that the controlling shares were apparently sold to an intermediary person and not directly to the probable RM candidate itself. I'm unsure if the intermediary will transfer/sell those shares to the new RM company or just keep them and they become part of the "original" shell share structure. Assuming they do not reverse split the stock prior to any RM, the final share count after the RM could be in the range of 550M to 2.3 billion (if the original shell owners retain 5-10% of the new company).
With a current share structure of 115+M shares the YCKM shell has a market cap of $20+M, so the shell is pretty richly valued at this moment in time. Plus there is still some debt on the books which will need to be addressed if the RM candidate doesn't wish to absorb it.
The world of shell investing is a pretty interesting thing. I get private messages from people saying that the SUIP shell is "way too expensive" in the 5-15 cent area (6.3M shares outstanding, $300K-$1M market cap), but those same people don't seem to have any concerns whatsoever about buying YCKM at a $20+M valuation. Interesting.
CDBH shell valuation...private messages.....
Over the last few weeks I have received a number of private messages stating that CDBH is an overvalued shell. Which is a bit puzzling to me because just basic, common sense fundamental analysis/math suggests otherwise.
From a purely fundamental perspective the CDBH shell has been consistently undervalued versus other Belmont/Meuse shells (as I have pointed out in past posts). And the contrast in valuations is also quite stark when you compare CDBH with some of the popular non-Belmont shells attracting attention here on IHUB.
CDBH is currently a 50K shares outstanding shell, deliquent on its last two quarterly filings, and a market cap of $100K/$450K at the bid/ask. Granted, shell valuations can always change due to unexpected or unforeseen pre-merger dilution, but that same caveat/condition applies to every other shell. Some of the more popular shells here on IHUB share a similiar filing status/condition as CDBH (deliquent or just recently became current with their filings).
So I think it is a bit difficult/ridiculous to label CDBH as being a "horribly overvalued shell" at a $450K market cap, when 100+M shares outstanding shells like NSCT and LOCN have been reaching market caps exceeding $10M (20X higher than CDBH).
db7...China consultant, job advertisements.....
"wow, lot's of possible sellers here? - "Dionics, Inc. (OTCBB:DION), a semiconductor/micro-electronics manufacturer known for its high-reliability PV (photo-voltaic) MOSFET-Drivers, today issued its Nine-Month and Q-3 reports for 2010 showing advancing sales volume over last year. Losses, however, widened as the company's program for increasing its sales in the large potential Chinese market-place required it to make a significant non-cash stock-compensation payment of 900,000 shares to its new Chinese consultants" "
I'm not anticipating any significant selling from the China consultant firm anytime soon. Based on the CEO's comments on the firm in recent press releases, and the fact that the firm was picked by CML (Roy Teng), I think the consultant firm is probably taking a "long-term" kind of perspective on DION.
That 11/3/2010 press release DION issued is quite interesting, IMO (particularly the parts referencing power-distribution applications and the consultant screening several merger/acquisition candidates). My eyebrow raised a little when I saw that, on the same day the PR came out, the consulting firm started placing DION job advertisements in China. The last ad that I was able to find was placed about two weeks ago and had a deadline of 11/26/2010.
The number of people they are looking to hire for a specific job requirement (financial audits/reports) seems unusually high, given DION's current level of business in China. Clearly, something is going on in the China market side of DION that is causing the consulting firm to look for 5 people who have experience with internal financial audits and preparation of financial reports/filings.
I am fully expecting to see some type of merger/acquisition activity within the next 12 months or so. Because of the relatively "tiny" size of DION right now, it is probably logical to believe that any M&A would potentially dramatically increase the size of the company. And perhaps in some respects any M&A activity might be viewed as somewhat of a reverse merger type of situation.
Although I am expecting to see CML (or perhaps associated individuals/institutions) inject additional cash into DION soon, the company currently has a market cap around $3M, and tradeable float under 5M shares. Some of the more popular shells currently on IHUB are selling for multiples of that valuation, with significantly larger floats.
nsomniyak...TGFN.....
"TGFN - Potse, do you think that Gaer now having accepted a position at FINRA will force him to make something happen with TGFN?"
That is what I am kind of hoping to see. Although it has always been Gaer's plan from Day One to bring in a new CEO to handle TGFN's new business, perhaps this latest career move will help "shake things up" a little. According to the 8-K his wife has taken his place on the Board of Directors, so the Gaers will still have an active/prominent say in the company's matters.
I'm encouraged to see that the person replacing Gaer as President has been given the title of "Interim President". Which suggests to me that: 1)Gaer/TGFN is still expecting to bring in a CEO/President to run or expand on the company's current business operations/plans, or 2) Gaer/TGFN is anticipating that some type of RM could still take place.
I figure with the stock trading at a significant discount to Gaer's financing, and the possibility of TGFN being somewhat of a "quasi-shell" at a still-reasonable valuation (comparatively speaking), it is probably worth having a few shares.
TGFN(.01)...Sam Gaer, largest shareholder.....
23.3M shares outstanding
$230K market cap
Has about $500K in upaid dividend debt (however the company apparently is liable only if it declares a dividend, which it has no plans to do).
Currently the company's operating business plan involves being a mobile applications incubator. IMO, at some point the company will significantly broaden out its current focus, and/or complete some type of merger/acquisition. From the plan of operations segment of the last quarterly report.....
Management's Plans are to seek App providers who wish to “equitize” their Apps’ potential by selling their developed App(s) for shares in TGFIN.
The company will always be open to other merger or acquisition candidates, depending upon the circumstances and opportunity offered. Management's main objective is to seek to increase shareholder value. All viable alternatives will be evaluated, including, but not limited to: investments, mergers, purchases, or the offering of Company securities, etc. Alternatives that provide existing shareholders with the greatest potential benefit will be favored.
Sam Gaer and his wife currently own more than 9M shares (38+% of the company). He has been providing financing to TGFN (convertible at 3 cents). Gaer just recently accepted a high level position at FINRA.....
http://www.finra.org/AboutFINRA/Leadership/P122397
TGFN website.....
http://stuff.nikol.ai/idev3/
SUIP...shell valuation, accumulation opportunity.....
The recent higher volume and churning is providing an attractive opportunity for shell investors to acquire sizable positions in SUIP in a short period of time. It is generally pretty difficult to establish 4-5% ownership of relatively high quality shells (low share structures, low net valuations), and especially difficult to acquire that kind of position at sub-$500K valuations.
Part of the reason why SUIP can be purchased at the current low valuation probably involves the nature of how SUIP came into existence (a spin-off shell, so many of the original investors most likely view SUIP as "free money"). IMO, shell investors who are willing to accept/ignore the volatility should be taking advantage of the current situation. With shells you can never really know/guess as to when the supply of shares dries up, but once that occurs and/or the float gets shifted into stronger hands accumulation will become significantly more difficult.
As I mentioned in my previous post, it is hard to ignore the extremely attractive fact that SUIP is trading at a sub-$200K valuation while all sorts of other shells in various stages of RM are reaching multi-million dollar valuations.
DION(.11)...advertising for China accountants......
Dionics placed an employment advertisement in China today. The company is looking for 5 people with accounting/audit experience. The primary job responsibility will be for internal financial audits and financial filings.
I think the number of people reflects the significant business/marketing expansion that DION is undergoing in China/Asia. It is also possible that it could have an immediate or future connection to something that was acknowledged in today's press release.....
Our Chinese consultants are also screening several candidates for possible growth through the Merger/Acquisition route.
DION job advertisement in China......
http://tinyurl.com/2ek9dn4
DION(.115)...11/03/2010 press release.....
Dionics, Inc. Announces Progress in "China-Initiative" With Several Key Events Aimed at Achieving Growth in Expanding Asian Market
Nov. 3, 2010 (GlobeNewswire) --
WESTBURY, N.Y., Nov. 3, 2010 (GLOBE NEWSWIRE) -- Dionics, Inc. (OTCBB:DION), a semiconductor/micro-electronics manufacturer known for its high-reliability PV (photo-voltaic) MOSFET-Drivers, today issued a progress-report on steps being taken to generate growth in the rapidly expanding Chinese market-place.
According to Bernard L. Kravitz, company president, "With the help of our new investors, CML, Ltd., we have taken significant steps toward promoting increased volume for our products in the vast China-market.
We have engaged the services of a highly-respected local Chinese consulting firm;
We have opened a Chinese-language website, www.Dionics-China.com;
Through our consultants, we have an operating sales/marketing function in Beijing;
We are in negotiations with a large number of electronics distributors who are interested in handling our high-reliability MOSFET-Drivers in the Chinese market-place;
Our Chinese consultants are also screening several candidates for possible growth through the Merger/Acquisition route.
Kravitz further explains that "in addition to the Chinese customers we already have, our growth program anticipates adding significant volume in power-distribution applications, an integral part of ongoing economic growth in China. Some potential high-quality situations will mature quickly, while others will need some time. Those situations that are more cost-sensitive must wait for completion of our aggressive, new cost-reduction program, already well under-way. Although the market potential for our products is incredibly large," Kravitz explained, "each specific situation involves its own unique balance between the cost of our product and the application-value of its high reliability. Our selling price, therefore, will determine how fast we can grow into that huge market potential. We intend to make our new, more competitive selling price, coupled with our already unchallenged high-reliability, a combination the Chinese market-place cannot resist," he concluded.
Forward-Looking Statements
Statements contained herein that are not based on current or historical fact are forward-looking in nature. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. When used herein, the words "anticipate", "believe", "estimate", "plan", "intend" and "expect"and similar expressions, as they relate to Dionics, Inc. or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects and opportunities to differ materially from those expressed or implied by these forward-looking statements. Certain of those factors are discussed in the Company's filings with the Securities and Exchange Commission. Except as required by the Federal Securities law, the Company does not undertake any obligations to release publicly any revisions to forward-looking statements to reflect events or circumstances after the date hereof or for any other reason.
CONTACT: Dionics, Inc.
Bernard L. Kravitz, President
(516) 997-7474
Sunrise Mining name reservation on Nev SOS......
I finished picking up some more shares. IMO, SUIP continues to be a fairly attractive shell, particularly when you compare it to some of the shells that have been getting quite a bit of attention on IHUB over the last few days/weeks/months. When you see shells with 100+M shares outstanding achieving market caps over $10M, I think a 6.3M share shell like SUIP trading at a $190K valuation offers a pretty interesting risk/reward.
Based on recent Nevada SOS filings, it is my hunch/belief that SUIP's management is still very much interested in acquiring mining assets/operations. For those who may not be familiar with some of the background/history on SUIP, the company changed its name to the current one of "Sunrise Holdings Limited" in March 2008. The change to a more "generic" name was done to reflect a potentially more diverse line of operations for the company, rather than just a mining-specific business.
I don't have text search capability on IHUB to see if anyone has noticed yet, but I would imagine that most investors are probably not aware of a rather interesting piece of information available on the Nevada SOS site. Shaojun Sun (SUIP's Vice President and CFO) filed a name reservation for "Sunrise Mining" about a week ago (October 25). So it wouldn't surprise me at all if some type of joint venture or RM with an Asia/China mining-related business takes place at some point.
Nevada SOS name reservation.....
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=VWOGlsmytnr3CtZH9QOWaw%253d%253d&nt7=0
DION(.115)...7M share float......
21M shares outstanding, 23.5M fully diluted
CEO/Directors own 14M shares
7M float
$2.5M market cap
Tiny, US-based semiconductor and integrated circuit company. In October 2009 foreign investors purchased majority control of the company (13M shares).
One of the new investors/directors is Roy Teng, a Managing Director of investment banking at Brean Murray, Carret & Co......
http://tinyurl.com/2frfjup
One notable non-insider who owns shares of DION is Alan Gelband (2.2M shares). Gelband has held this large block of shares for a number of years, so that takes the number of shares "available" in the float probably down under 5M shares.....
http://www.gelband.com/index.html
DION websites.....
http://www.dionics-usa.com/
http://www.dionics-china.com/
DION(.115)...semiconductors, China website.....
The Chinese website for DION was registered on October 8. It is not entirely functioning/updated correctly, but it is one more step toward what I anticipate will be a significantly improving future for the company.
As I have mentioned in other posts about this particular stock, I continue to believe that DION is not receiving the attention it probably should be getting. When you have Roy Teng (a managing director at Brean Murray, Carret & Co) and his father purchase majority control of DION, it is something worth noting. Teng's position at Brean Murray's China office involves a great deal of investment banking work with small/medium companies in China. As such, Teng has significant insight/contacts across China and a pretty good knowledge base of private companies looking to go public. That makes his personal investment/involvement with DION quite interesting, as I do expect that at some point in DION's future a merger/acquisition strategy will be implemented.
In the last couple of years DION has shown the ability to be basically break-even or profitable on less than $1M in revenue, which IMO is pretty interesting for a high-tech kind of company like this. I am unsure how the increased marketing presence in China might impact the near-term expense line, but relatively "minor" improvements in revenue could very well have significant positive impacts on the bottom line (margin improvements as a result of facility utilization, etc).
Fully-diluted share count is less than 25M (includes a $250K note that CEO Bernard Kravitz can convert at 9 cents). Also worth noting that as part of the change in control the CEO has a put option agreement in which he can sell 1M shares of his personal holdings to the new investors at a price in the .30-.80 range when his employment contract expires in October 2011.
China website.....
http://www.dionics-china.com/index.asp
futrcash...CEO debt, quarterly filing comment.....
Together with HemoGenix, Inc, with whom the Company formed a strategic alliance in April 2010, we jointly exhibited at this meeting and launched new products for advanced testing of stem cells known as mesenchymal stem cells and induced pluripotent stem cells, which are types of adult stem cells of considerable research and clinical interest. We established contact with numerous prospective customers and also engaged in discussions with several prospective collaborators. From these initial contacts, the Company has on-going discussions regarding the establishment of a distribution contract with a leading global supplier of life sciences products. The Company intends to pursue this opportunity to the full extent possible since management believes this is a strong opportunity to realize increased revenue in the immediate future. We further engaged in discussions with a partner for the development of media for use in the production of stem cell-derived food while at the ISSCR, together with other potential collaborators and customers. Product sales increased compared to the previous quarter (See “Results of Operations”) and we continue to focus our efforts on increased revenue growth during the Company’s 4th fiscal quarter and beyond. Management is engaged with numerous current and prospective customers regarding product sales and there are several opportunities for collaboration with other firms and university researchers working in the stem cell sector that may lead to strategic alliances further expanding sales of the Company’s products and development of new products targeting stem cell research and drug development. Also, there is renewed interest by an offshore third party in commercialization of the Company’s fertility drug product and technology portfolio.
In addition to the above information and delivery of the prototype culture media subsequent to the quarter's end, the filing contained an interesting comment about the CEO's accrued salary/debt (see below). To the best of my knowledge this is the first time I recall this type of statement/comment being made in a filing since that early 2008 financing.
For those who don't recall, when VODG entered into that initial 2008 financing the terms of the financing required that the CEO's accrued salary/debt would be reorganized through a two-stage process. The first stage was done with the issuance of some shares, however the second stage has never been completed yet. The second stage basically consisted of the CEO forgiving all his accrued salary/debt above $500K and placing the remaining amount into a promissory note which would be convertible at $1.
Given the length of time that has elapsed since that financing, or the possibility that the investors may have simply waived the requirement, it is entirely possible that the terms of the second stage may no longer be implemented. However, in my opinion, if the CEO/company were to enact that phase (under the original terms, or similiar shareholder friendly terms), I think you would see a noticeably positive market reaction.
Statement in the last quarterly report.....
The majority of the working capital deficit and the shareholders’ equity deficit is due to accrued salaries and notes due to the president and CEO which management intents to reduce in the future through appropriate measures.
Viking...job ads, TBJK reverse merger.....
Viking Investments (majority owner of SBAT) has continued placing job advertisements for its Shanghai office since I first noticed its pickup of activity in December 2009. Employment positions have ranged from interns, receptionists, business development people to work with Viking's corporate clients, and people skilled in English/Chinese translations of business documents/correspondence.
I recall in late March/April (shortly after SBAT returned to shell status) that one of the business development ads specifically mentioned that the employee would be working with a Shandong client ready for a US-listing.
It might be worth noting that Viking Investments was a key consultant on the very recent TBJK reverse merger. The initial post-merger share structure of TBJK (prior to a completed subsequent financing at $4) is 10M shares outstanding, with Viking retaining about 5.6% (560+K shares).
Prior to the announcement of the RM, the TBJK shell with 429M shares outstanding reached a valuation over $6M. The private placement was done at a shell valuation over $3M. As I type this post, the current valuation of the TBJK shell shares is over $2M.
For comparison purposes, the SBAT shell with 1M shares outstanding has a current valuation of $300K.
VODG...Aubrey, Inc.....
A 9/15/2010 article published in ePlasty (plastic and reconstructive surgery journal) contains an interesting piece of information. It appears that VODG's stem cells and culture media were used by Aubrey, Inc for some research/testing on one of the configurations of its AWBAT Plus product.
The lead author/researcher on the article is Aubrey Woodroof (CEO of Aubrey, Inc). Some biographical information about Woodroof from an Aubrey press release.....
Dr. Aubrey Woodroof invented Biobrane® in 1978, an innovative product which revolutionized the burn care industry and helped burn survivors around the world to heal better and faster. Biobrane® maintains a key role in burn management to this day, over 30 years later. At the end of 2007, Woodroof came out of retirement to form Aubrey Inc. and to create AWBAT, the next generation of advanced wound care technology. Aubrey Inc. is headquartered in Carlsbad, CA.
http://www.prnewswire.com/news-releases/aubrey-inc-receives-fda-clearance-for-awbat-plus-82914507.html
AWBAT Plus received FDA approval in January 2010. I picked out a few of the relevant pieces of information from the ePlasty article.....
1) Title: The Search for an Ideal Temporary Skin Substitute: AWBAT Plus, a Combination Product Wound Dressing Medical Device
2) Human mesenchymal stem cells (MSC), derived from human cord blood, were purchased as a viable culture (Vitro Biopharma, Golden, CO) and were maintained in low serum mesenchymal stem cell culture medium without antibiotics or antimycotic. To test the growth on the AWBAT-S Plus (nylon mesh side up) 5.0 × 105 MSC were plated onto the material in the bottom of a 24 well plate.
3) Of interest is the finding shown here that human mesenchymal stem cells grow well on AWBAT Plus. This finding shows that in the future, stem cells themselves or stem cells differentiated to different kinds of skin cells could readily be used with AWBAT Plus or be already attached to AWBAT Plus to serve as a living “skin” replacement.
ePlasty article.....
http://www.eplasty.com/index.php?option=com_content&view=article&id=479&catid=15&Itemid=116
Aubrey, Inc. website.....
http://www.aubreyinc.com/index.html
China Domestica website.....
The China Domestica Bio-technology Holdings website was registered on September 14 (a little less than 2 weeks ago). The site started coming online within the last 1-2 days......
http://www.chinadomestica.com/
MWM...NXPN debt obligations.....
"Everyone is so afraid of the R/S but I think this is a steal either way, if they r/s it under .01 it's stil going to be under .10 and have a tiny market cap...
The only downside is that High Plains Gas must be a new company because I can not find out much about it on the web. With Mark Hettinger's experience I think this is worth a shot..."
I think one area of concern regarding this particular RM probably centers around the two debt obligations that exist. If I recall correctly from the mental notes I took, there is a $20+K floorless convertible debt owed to the interim CEO and a $280+K debt (no repayment terms disclosed/announced) held by Guy Peckham (former CEO of EWRL, and one of the individuals who purchased majority control of the shell).
Unfortunately neither the 8-K or other filings gave any clue/details on exactly how the debt will be resolved, so there is really no way of knowing what (if any) impact the debt might have on pre/post merger dilution. The wording in the reorganization agreement is a bit curious, because it potentially suggests the possibility of some pre-split dilution if the reverse split scenario is enacted. Notice that in the "cancellation" part of the agreement, the company provides an exact number of shares that would be cancelled, so you know exactly what the outstanding share count is prior to the cancellation. However, in the "reverse split" section of the agreement, the company does not provide any RS ratio......
NXPN shall either complete a reverse split of its common stock or cancel or cause to be cancelled a total of 86,720,000 shares of its common stock such that at Closing there shall be a total of 13,000,000 shares of common stock issued and outstanding.
georgia34...GNZR financing.....
"No link. Can only go by the letter that I received as a Scientigo note holder who signed away find.com to Generation Zero in exchange for a re-structured Generation Zero note. Got paid a sliver of principal before the closing, but have not received a second payment as promised, (was supposed to occur thirty days after find.com closing).
I was told by a member of the advisory board for Gen Zero, that the company had not raised sufficient capital in order to make the second principal payment, (this amount totals $250,000).
My concern is that by not making this payment on time, it suggests that the company is hurting for capital. The money certainly will not come from beach.org ad profits. Hopefully, they will find some suckers pretty soon, and get me paid."
I sold my position in GNZR awhile back when I started becoming extremely uncomfortable with some of the business/financial decisions that GNZR management was making (in particular, the handling of the convertible debt -- see posts below).
I think in one of my previous posts on this board I mentioned the only reason(s) I could envision for Matthew Krieg's interest in maintaining such dilutive debt was if the debt holders had some assets that would be transferred to GNZR at an extremely attractive price, or if the debt holders would be providing financing at attractive terms.
One of GNZR's debt holders is facing SEC fraud charges on another stock/investment, so I think it is now highly unlikely that anything "positive" will result from that convertible debt. IMO, the combination of the fully-diluted share count and the legal issues surrounding one of the debt holders is probably going to make it very difficult for GNZR to raise a significant amount of money at reasonably attractive terms from outside/independent investors and institutions.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=52393913
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=52590703
Management commentary from Q2......
Management is encouraged by improvements in the First Half of 2010 but, based on the slowing trend in the Second Quarter, believes that at best a modest economic turnaround is taking place. We also anticipate the traditional Third Quarter slowdown in our industry, pushing a more vigorous upturn into the later part of the year.
We are, however, optimistic regarding the outlook for material assistance in sales opportunities in the Far East stemming from our new investor, CML. With their assistance, we have engaged a Consulting firm in China, have already established a Chinese language website there, and initiated the beginnings of a sales office there, as well. Our primary product, photo-voltaic (PV) MOSFET-Drivers are becoming increasingly popular in China, as well as domestically. In addition, we are also looking forward to other growth opportunities that may be provided through the assistance of our new investor and, needless to say, their injection of working capital late in 2009 provides us with increased means of pursuing growth in a variety of directions. Our focus is now on the future.
VODG(.15)...stem cell-derived food.....
The two announced business relationships that VODG has attracted in the last 4 months or so are pretty interesting, IMO.
With the addition of an investment banker to VODG's Board of Directors, and the CEO's mention in his May 18 shareholder letter that the strategic alliance VODG and HemoGenix have formed "may lead to an appropriate business combination", I think the possibility of some merger/acquisition activity involving VODG has significantly increased.
The contract with Mokshagundam Biotechnologies expands the use of VODG's products/technologies beyond just the medical arena. VODG's cell culture media and cellular immortalization technology could ultimately find its way into the commercial production of stem cell-derived meat for consumption by animals/humans.....
Dr. Jim Musick, Vitro’s CEO said, “We are pleased to be involved with this ground breaking opportunity to extend stem cell technology to development of alternative food sources. Cellular immortality as reflected in continual stem cell proliferation (self-renewal) has potential to provide limitless cells that when differentiated to muscle, for example, become the primary ingredient of meat. This reflects the basis of alternative food derived from stem cells that is now being developed. We intend to use our expertise in stem cell media development and commercial manufacture to provide appropriate media formulations to support this nascent technology. Our VITROGROW™ Brand of stem cell media has been demonstrated to result in superior performance to competing products in the growth of human adult stem cells and is now utilized in high performance, bioluminescent test kits (Lumenesc-Hu™ and LumiSTEM™) for measuring the quality and potency of mesenchymal and induced-pluripotent stem cells. We anticipate contributing to this exciting new field and plan to further develop cellular immortalization procedures that may be crucial to economic production of stem cell-derived meat.”
http://www.vitrobiopharma.com/investorrelations/press22.html
This is a link to Kedar Challakere's (Mokshagundam Biotechnologies) patent application......
http://www.wipo.int/pctdb/en/wo.jsp?WO=2010068897&IA=US2009067721&DISPLAY=DESC